Eli Lilly is offering expanded access to retatrutide, its investigational triple hormone receptor agonist that demonstrated substantial weight loss in phase 3 ... Show more
Story Details
| Last Updated | |
| Total Articles | 1 |
Main Topics
Similar to This
Previous
Lilly’s retatrutide outshines Ozempic on weight loss, blood sugar control in trial
bnnbloomberg.ca/business/company-news/2026/10/28/lillys-retatrutide-outshines-ozempic-on-weight-loss-blood-sugar-control-in-trial/
STAT Oct 28
Lilly’s triple-G drug beats Ozempic in head-to-head study: Today's biotech news includes two deaths reported in cell therapy autoimmune trial ...
statnews.com/2026/10/28/biotech-news-lillys-triple-g-drug-beats-ozempic-in-head-to-head-study/
Paid articlePaywall
The Most Powerful Obesity Drug Yet Has a Hidden Benefit—and It Happens While You Sleep
gizmodo.com/the-most-powerful-obesity-drug-yet-has-a-hidden-benefit-and-it-happens-while-you-sleep-2000830582
STAT Oct 20
A bipartisan group of lawmakers urges the FDA to close a peptide loophole: A bipartisan group of lawmakers is urging the FDA to plug a loophole used to import ...
statnews.com/2026/10/20/health-policy-news-bipartisan-group-of-lawmaker-urges-fda-to-close-peptide-loophole/
Paid articlePaywall
BBC Sep 05
Retatutride: How the hunger for a new weight loss drug is feeding an industry of fakes
bbc.co.uk/news/articles/cwyz7lrwqdyo
Eli Lilly tries to stop GLP-1 copycats: Eli Lilly said it filed six lawsuits against US companies it accused of selling illicit versions of its experimental ...
semafor.com/article/08/12/2026/eli-lilly-tries-to-stop-glp-1-copycats
Eli Lilly's experimental diabetes drug helped patients lose 17% of their body weight
qz.com/eli-lilly-retatrutide-diabetes-weight-loss
OpinionThe Next Wave Of Weight-Loss Drugs Is Here—And It Targets Three Hormones, Not One
womenshealthmag.com/health/a69731026/triple-agonist-weight-loss-medication-clinical-trial/
OpinionThe Next Wave Of Weight-Loss Drugs Is Here—And It Targets Three Hormones, Not One
womenshealthmag.com/health/a69731026/triple-agonist-weight-loss-medication-clinical-trial/
OpinionThe Next Wave Of Weight-Loss Drugs Is Here—And It Targets Three Hormones, Not One
womenshealthmag.com/health/a69731026/triple-agonist-weight-loss-medication-clinical-trial/
OpinionThe Next Wave Of Weight-Loss Drugs Is Here—And It Targets Three Hormones, Not One
womenshealthmag.com/health/a69731026/triple-agonist-weight-loss-medication-clinical-trial/
OpinionThe Next Wave Of Weight-Loss Drugs Is Here—And It Targets Three Hormones, Not One
womenshealthmag.com/health/a69731026/triple-agonist-weight-loss-medication-clinical-trial/
OpinionThe Next Wave Of Weight-Loss Drugs Is Here—And It Targets Three Hormones, Not One
womenshealthmag.com/health/a69731026/triple-agonist-weight-loss-medication-clinical-trial/
OpinionThe Next Wave Of Weight-Loss Drugs Is Here—And It Targets Three Hormones, Not One
womenshealthmag.com/health/a69731026/triple-agonist-weight-loss-medication-clinical-trial/
OpinionThe Next Wave Of Weight-Loss Drugs Is Here—And It Targets Three Hormones, Not One
womenshealthmag.com/health/a69731026/triple-agonist-weight-loss-medication-clinical-trial/
OpinionThe Next Wave Of Weight-Loss Drugs Is Here—And It Targets Three Hormones, Not One
womenshealthmag.com/health/a69731026/triple-agonist-weight-loss-medication-clinical-trial/
OpinionThe Next Wave Of Weight-Loss Drugs Is Here—And It Targets Three Hormones, Not One
womenshealthmag.com/health/a69731026/triple-agonist-weight-loss-medication-clinical-trial/
OpinionThe Next Wave Of Weight-Loss Drugs Is Here—And It Targets Three Hormones, Not One
womenshealthmag.com/health/a69731026/triple-agonist-weight-loss-medication-clinical-trial/
Next